Paris, France-based Implanet released the company's 2014 financial report.
"We are highly optimistic for the future, notably because of strict structural cost management and the substantial success of our recent capital increase, which has given us the resources to accelerate JAZZ's expansion in spine surgery and make it a global benchmark in healthcare," said Implanet CEO Ludovic Lastennet.
Here are 11 things to know from the company's report:
1. Last year Implanet reported strong revenue growth, increasing 28 percent, led by spine activity.
2. There were 4,260 JAZZ implants sold in 2014.
3. The company underwent a rapid restructuring of the United States subsidy and was able to meet sales targets last year.
4. In 2014, the company generated knee platform growth and discontinued hip activity, which had an impact but will disappear in early 2015.
5. French sales were 57 percent of all revenue while the United States subsidy was 12 percent of revenue.
6. In the United States last year reached $1 million in sales during the first full year.
7. The gross margin was 41.7 percent, up 4.2 percentage points reflecting a higher contribution of increased JAZZ sales to the mix.
8. Operating costs were up over last year, the most significant being investment in the Implanet America subsidy. The company reported an operating loss and net loss last year when taking all elements of the financial situation into account.
9. Implanet currently has a 45-person workforce with six people in the United States.
10. The company plans to accelerate down the roadmap it laid out with its IPO and continue with studies and publications associated with its devices.
11. A current medico-economic study in the Untied States shows the cost-benefit of the JAZZ at around $11,700 per surgical procedure; additional encouraging preliminary results are coming out of the Mayo Clinic where researchers were examining an in-vitro biomedical study in osteoporotic specimens.